Compare Revvity Inc (RVTY) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Vanguard Intermediate Term Corporate Bond ETF trades at $80.48. The key difference: Revvity Inc pays a 0.22% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | VCIT | |
|---|---|---|
Market Cap | $14.18B | — |
Sector | Technology | Fixed Income |
52-Week High | $130.94 | $84.82 |
52-Week Low | $82.26 | $80.31 |
Enterprise Value | $16.50B | — |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
VCIT trades at $80.46, down 0.09% on the day, with a bearish technical signal from moving averages but bullish oscillators. The ETF offers a 4.8% yield and low 0.03% expense ratio, attracting institutional interest as seen with HB Wealth Management increasing holdings by 242.9% in Q3 2026 (SEC filing, September 2026). Recent news highlights its competitive edge in intermediate-term corporate bonds.
The outlook remains favorable for income investors seeking yield with moderate risk, though bearish momentum and interest rate sensitivity pose near-term headwinds. Key opportunities include cost efficiency and diversification, while risks involve market volatility and economic shifts affecting corporate credit.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
